Elonda 0.5Mg 2 Tap 6224008365341

Elonda 0.5Mg 2 Tap 6224008365341

Description:

Elonda 0.5 mg is a prescription medicine containing cabergoline, a long-acting dopamine agonist and potent prolactin inhibitor. It is primarily used to treat hyperprolactinemic disorders (high prolactin levels), including conditions caused by prolactin-secreting pituitary adenomas (prolactinomas), and may also be used in the management of Parkinson’s disease as monotherapy or as an adjunct to levodopa in advanced stages. By selectively stimulating dopamine d2 receptors, Elonda helps normalize prolactin levels, restore hormonal balance, and alleviate related symptoms such as menstrual disturbances, galactorrhea, and infertility.

Indications:

• Treatment of hyperprolactinemic disorders, idiopathic or due to prolactin-secreting pituitary adenomas (prolactinomas).
• Management of clinical symptoms associated with high prolactin levels, such as amenorrhea, oligomenorrhea, anovulation, galactorrhea, and infertility related to hyperprolactinemia.
• Reduction of prolactin levels and tumor size in patients with prolactin-secreting pituitary adenomas, where indicated by a physician.
• Adjunctive or monotherapy in the management of Parkinsonian syndrome, especially in patients requiring dopamine agonist therapy (as directed by a specialist).

Active Ingredients / Key Components:

• Cabergoline – 0.5 mg per tablet
• Excipients: Information on inactive ingredients (excipients, fillers, binders, coloring agents) is not available in the provided data. Refer to the official package leaflet for the full list of excipients.

Dosage & Administration / How to Use:

• Use only as prescribed by a physician experienced in treating hyperprolactinemia or Parkinson’s disease.
• Typical dosage for hyperprolactinemia (adults): Initial dose is usually 0.25 mg twice weekly, adjusted gradually based on prolactin levels and clinical response. The 0.5 mg strength allows flexible dosing (e.g., 0.5 mg once weekly or divided as directed). Exact regimen must be determined by the doctor.
• Parkinson’s disease: Dose and titration schedule are individualized and usually start at a low dose, gradually increased under strict medical supervision. Do not change the dose without consulting your neurologist.
• Tablets are taken orally with water, preferably with food to improve gastrointestinal tolerance.
• Take at the same days each week if prescribed as a weekly or twice-weekly regimen (e.g., Monday and Thursday), to help remember doses.
• If you miss a dose, take it as soon as you remember unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed one.
• Do not stop treatment abruptly without medical advice, especially if used for Parkinson’s disease; the dose may need to be tapered.

Clinical Benefits:

• Effectively lowers elevated prolactin levels, helping restore normal hormonal balance.
• Improves reproductive function in hyperprolactinemic patients, supporting normalization of menstrual cycles and ovulation, and potentially improving fertility.
• Reduces or resolves symptoms such as galactorrhea, amenorrhea, and related discomfort caused by high prolactin.
• Provides long-acting dopamine d2 receptor stimulation, allowing less frequent dosing compared to some other dopamine agonists.
• In Parkinson’s disease, helps improve motor symptoms (such as rigidity and bradykinesia) when used as monotherapy or as an adjunct to levodopa, as directed by a specialist.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to cabergoline, other ergot derivatives, or any component of the formulation.
• Contraindicated in patients with a history of fibrotic disorders affecting the lungs, pericardium, or retroperitoneum, or with evidence of cardiac valvular disorders (valvulopathy), unless the treating physician decides otherwise after appropriate evaluation.
• Use with extreme caution in patients with severe cardiovascular disease, hypotension, uncontrolled hypertension, liver impairment, or history of serious psychiatric disorders (especially psychosis).
• May cause symptomatic hypotension, particularly at treatment initiation; caution is advised when driving or operating machinery.
• Regular monitoring of blood pressure, cardiac function (including echocardiography when indicated), and prolactin levels is recommended during long-term therapy.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Cabergoline is generally not recommended during pregnancy unless clearly needed, and breastfeeding is usually not advised while taking cabergoline due to its prolactin-suppressing effect.
• Inform your doctor about all other medications you are taking, especially other dopamine agonists, antipsychotics, antihypertensives, macrolide antibiotics (e.g., erythromycin), or drugs affecting blood pressure.
• Not intended for use without medical supervision and not suitable for self-diagnosis or self-treatment.
• Keep out of reach of children.

Side Effects:

• Common side effects may include nausea, vomiting, stomach discomfort, constipation, dizziness, headache, fatigue, and low blood pressure (especially when standing up).
• Other possible side effects: flushing, palpitations, peripheral edema, sleep disturbances, depression, or nervousness.
• Serious but less common side effects may include cardiac valvulopathy, pleural effusion, pulmonary fibrosis, retroperitoneal fibrosis, severe hypotension, hallucinations, or psychotic reactions, particularly at higher doses or in Parkinson’s patients.
• Impulse control disorders (such as pathological gambling, increased libido, or compulsive spending) have been reported with dopamine agonists; inform your doctor if you or your family notice such behavior changes.
• Seek immediate medical attention if you experience chest pain, difficulty breathing, persistent cough, swelling of legs, severe abdominal pain, sudden severe headache, visual disturbances, or signs of an allergic reaction (rash, itching, swelling of face or throat, difficulty breathing).

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date printed on the pack. Store at or below the temperature specified on the original packaging (exact storage temperature is not available in the provided data; refer to the product leaflet).

Specifications:

• Strength: 0.5 mg cabergoline per tablet.
• Form: Oral tablets.
• Pack size: 2 tablets per pack (2 tabs).
• Intended use: Prescription medicine for adults, under medical supervision.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.